Abstract
AbstractThe sources of information on regulatory requirements for licensing (marketing authorisation) of pharmaceuticals in the European Community, including aspects applying to macromolecular excipients, are identified. The pharmaceutical, preclinical and clinical implications are discussed in outline.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have